The use of gene therapy in cancer research and treatment

Technology in Cancer Research and Treatment

Volumn 3, Issue 5, 2004, Pages 479-490

  Shinohara, Eric T ^a   Lu, Bo ^a   Hallahan, Dennis E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; FLICE INHIBITORY PROTEIN; GENE PRODUCT; INHIBITOR OF APOPTOSIS PROTEIN; MELAN A; MONOPHENOL MONOOXYGENASE; MUCIN 1; ONYX 015; ONYX 411; PROTEIN BAX; PROTEIN MDM2; PROTEIN P14; PROTEIN P35; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; SURVIVIN; THYMIDINE KINASE; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

CANCER RESEARCH; CLINICAL TRIAL; DNA VECTOR; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REVIEW; SIDE EFFECT; SUICIDE GENE THERAPY; TECHNIQUE; TECHNOLOGY; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

EID: 6344272895     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460400300509     Document Type: Review

References (126)

1. Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J. P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., Fischer, A., Davies, E. G., Kuis, W., Leiva, L., and Cavazzana-Calvo, M. Sustained Correction of X-linked Severe Combined Immunodeficiency by Ex Vivo Gene Therapy. N. Engl. J. Med. 346, 1185-1193 (2002).
2. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Le Deist, F., Fischer, A., and Cavazzana-Calvo, M. LMO2-associated Clonal T Cell Proliferation in Two Patients After Gene Therapy for SCID-X1. Science 302, 415-419 (2003).
3. Williams, D. A. and Baum, C. Medicine. Gene Therapy - New Challenges Ahead. Science 302, 400-401 (2003).
4. Schuler, M., Herrmann, R., De Greve, J. L., Stewart, A. K., Gatzemeier, U., Stewart, D. J., Laufman, L., Gralla, R., Kuball, J., Buhl, R., Heussel, C. P., Kommoss, F., Perruchoud, A. P., Shepherd, F. A., Fritz, M. A., Horowitz, J. A., Huber, C., and Rochlitz, C. Adenovirus-mediated Wild-type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-small-cell Lung Cancer: Results of a Multicenter Phase II Study. J. Clin. Oncol. 19, 1750-1758 (2001).
5. Harvey, B. G., Leopold, P. L., Hackett, N. R., Grasso, T. M., Williams, P. M., Tucker, A. L., Kaner, R. J., Ferris, B., Gonda, I., Sweeney, T. D., Ramalingam, R., Kovesdi, I., Shak, S., and Crystal, R. G. Airway Epithelial CFTR mRNA Expression In Cystic Fibrosis Patients After Repetitive Administration of a Recombinant Adenovirus. J. Clin. Invest. 104, 1245-1255 (1999).
6. Stolberg, S. G. The Biotech Death of Jesse Gelsinger. NY Times Mag. 136-140, 149-150 (1999).
7. Smith, L. and Byers, J. F. Gene Therapy in the Post-Gelsinger Era. JONAS Healthc Law Ethics Regul. 4, 104-110 (2002).
8. Chen, L. and Waxman, D. J. Cytochrome P450 Gene-directed Enzyme Prodrug Therapy (GDEPT) for Cancer. Curr. Pharm. Des. 8, 1405-1416 (2002).
9. Sturtz, F. G., Waddell, K., Shulok, J., Chen, X., Caruso, M., Sanson, M., Snodgrass, H. R., and Platika, D. Variable Efficiency of the Thymidine Kinase/Ganciclovir System in Human Glioblastoma Cell Lines: Implications for Gene Therapy. Hum. Gene Ther. 8, 1945-1953 (1997).
10. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M. Tumors Expressing the Cytosine Deaminase Suicide Gene Can Be Eliminated In Vivo with 5-fluorocytosine and Induce Protective Immunity to Wild Type Tumor. Cancer Res. 54, 1503-1506 (1994).
11. Aswaq, M., Richards, V., and McFadden, S. Immunologic Response to Autologous Cancer Vaccine. Arch. Surg. 89, 485-487 (1964).
12. Hege, K. M. and Carbone, D. P. Lung Cancer Vaccines and Gene Therapy. Lung Cancer 41 Suppl 1, S103-113 (2003).
13. Im, S. S., Monk, B. J., and Villarreal, L. P. Prevention of Cervical Cancer with Vaccines. Curr. Oncol. Rep. 3, 322-328 (2001).
14. Lowy, D. R. and Schiller, J. T. Papillomaviruses and Cervical Cancer: Pathogenesis and Vaccine Development. J. Natl. Cancer Inst. Monogr. 27-30 (1998).
15. Gissmann, L., Osen, W., Muller, M., and Jochmus, I. Therapeutic Vaccines for Human Papilloma-viruses. Intervirology 44, 167-175 (2001).
16. Hersey, P., Menzies, S. W., Halliday, G. M., Nguyen, T., Farrelly, M. L., DeSilva, C., and Lett, M. Phase I/II Study of Treatment with Dendritic Cell Vaccines in Patients with Disseminated Melanoma. Cancer Immunol. Immunother. 53, 125-134 (2004).
17. Tagawa, S. T., Lee, P., Snively, J., Boswell, W., Ounpraseuth, S., Lee, S., Hickingbottom, B., Smith, J., Johnson, D., and Weber, J. S. Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma. Cancer 9, 144-154 (2003).
18. Pantuck, A. J., van Ophoven, A., Gitlitz, B. J., Tso, C. L., Acres, B., Squiban, P., Ross, M. E., Belldegrun, A. S., and Figlin, R. A. Phase I Trial of Antigen-specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-positive Patients with Advanced Prostate Cancer. J. Immunother. 27, 240-253 (2004).
19. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-macrophage Colony-stimulating Factor Stimulates Potent, Specific, and Long-lasting Anti-tumor Immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543 (1993).
20. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J.C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K. K., Cosimi, A. B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Dranoff, G. and et al. Vaccination With Irradiated Autologous Melanoma Cells Engineered to Secrete Human Granulocyte-macrophage Colony-stimulating Factor Generates Potent Antitumor Immunity in Patients With Metastatic Melanoma. Proc. Natl. Acad. Sci. USA. 95, 13141-13146 (1998).
21. Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. I., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., Hauda, K. M., Beck, L. A., Leiferman, K. M., Owens, A. H. Jr., Piantadosi, S., Dranoff, G., Mulligan, R. C., Pardoll, D. M., and Marshall, F. F. Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-macrophage Colony-stimulating Factor Gene Transfer. Cancer Res. 57, 1537-1546 (1997).
22. Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M., Weber, C. E., Baccala, A. A., Goemann, M. A., Clift, S. M., Ando, D. G., Levitsky, H. I., Cohen, L. K., Sanda, M. G., Mulligan, R. C., Partin, A. W., Carter, H. B., Piantadosi, S., Marshall, F. F., and Nelson, W. G. Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination With Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-macrophage Colony-stimulating Factor Using Ex Vivo Gene Transfer. Cancer Res. 59, 5160-5168 (1999).
23. Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F. S., Jaklitsch, M., Mentzer, S., Swanson, S., Lukanich, J., Bueno, R., Wain, J., Mathisen, D., Wright, C., Fidias, P., Donahue, D., Clift, S., Hardy, S., Neuberg, D., Mulligan, R., Webb, I., Sugarbaker, D., Mihm, M., and Dranoff, G. Vaccination with Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-macrophage Colony-stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non-small-cell Lung Carcinoma. J. Clin. Oncol. 21, 624-630 (2003).
24. Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., Lillemoe, K. D., O'Reilly, S., Abrams, R. A., Pardoll, D. M., Cameron, J. L., and Yeo, C. J. Novel Allogeneic Granulocyte-macrophage Colony-stimulating Factor-secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. J. Clin. Oncol. 19, 145-156 (2001).
25. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., Robinson, M. R., Raffeld, M., Duray, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., Mavroukakis, S. A., White, D. E., and Rosenberg, S. A. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science 298, 850-854 (2002).
26. Nguyen, D. M., Spitz, F. R., Yen, N., Cristiano, R. J., and Roth, J. A. Gene Therapy for Lung Cancer: Enhancement of Tumor Suppression by a Combination of Sequential Systemic Cisplatin and Adenovirus-mediated p53 Gene Transfer. J. Thorac. Cardiovasc. Surg. 112, 1372-1376; Discussion 1376-1377 (1996).
27. Kuball, J., Wen, S. F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D.C., Grace, M. J., Fritz, M. A., Storkel, S. J., Thuroff, W., Huber, C., and Schuler, M. Successful Adenovirus-mediated Wild-type p53 Gene Transfer in Patients with Bladder Cancer by Intravesical Vector Instillation. J. Clin. Oncol. 20, 957-965 (2002).
28. Pagliaro, L. C., Keyhani, A., Williams, D., Woods, D., Liu, B., Perrotte, P., Slaton, J. W., Merritt, J. A., Grossman, H. B., and Dinney, C. P. Repeated Intravesical Instillations of an Adenoviral Vector in Patients with Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy. J. Clin. Oncol. 21, 2247-2253 (2003).
29. Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M.D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., Chandler, W., Zwiebel, J. A., Kaplan, R. S., and Yung, W. K. Phase I Trial of Adenovirus-mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results. J. Clin. Oncol. 21, 2508-2518 (2003).
30. McNeish, I. A., Bell, S. J., and Lemoine, N.R. Gene Therapy Progress and Prospects: Cancer Gene Therapy Using Tumour Suppressor Genes. Gene Ther. 11, 497-503 (2004).
31. Zeimet, A. G. and Marth, C. Why Did p53 Gene Therapy Fail in Ovarian Cancer? Lancet Oncol. 4, 415-422 (2003).
32. Wolf, B. B., Schuler, M., Li, W., Eggers-Sedlet, B., Lee, W., Tailor, P., Fitzgerald, P., Mills, G. B., and Green, D. R. Defective Cytochrome C-dependent Caspase Activation in Ovarian Cancer Cell Lines Due to Diminished or Absent Apoptotic Protease Activating Factor-1 Activity. J. Biol. Chem. 276, 34244-34251 (2001).
33. Zhang, Z. L., Zou, W. G., Luo, C. X., Li, B. H., Wang, J. H., Sun, L. Y., Qian, Q. J., and Liu, X. Y. An Armed Oncolytic Adenovirus System, ZD55-gene, Demonstrating Potent Antitumoral Efficacy. Cell Res. 13, 481-489 (2003).
34. Wildner, O. and Morris J. C. The Role of the E1B 55 kDa Gene Product in Oncolytic Adenoviral Vectors Expressing Herpes Simplex Virus-tk: Assessment of Antitumor Efficacy and Toxicity. Cancer Res. 60, 4167-4174 (2000).
35. Nemunaitis, J., Cunningham, C., Tong, A. W., Post, L., Netto, G., Paulson, A. S., Rich, D., Blackburn, A., Sands, B., Gibson, B., Randlev, B., and Freeman, S. Pilot Trial of Intravenous Infusion of a Replication-selective Adenovirus (ONYX-015) in Combination with Chemotherapy or IL-2 Treatment in Refractory Cancer Patients. Cancer Gene Ther. 10, 341-352 (2003).
36. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J., and Kirn, D. Intra-arterial Administration of a Replication-selective Adenovirus (d11520) in Patients with Colorectal Carcinoma Metastatic to the Liver: A Phase I Trial. Gene Ther. 8, 1618-1626 (2001).
37. Vasey, P. A., Shulman, L. N., Campos, S., Davis, J., Gore, M., Johnston, S., Kirn, D. H., O'Neill, V., Siddiqui, N., Seiden, M. V., and Kaye, S. B. Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-gene-deleted Adenovirus ONYX-015 (d11520) Given on Days 1 Through 5 Every 3 Weeks in Patients with Recurrent/Refractory Epithelial Ovarian Cancer. J. Clin. Oncol. 20, 1562-9 (2002).
38. Hecht, J. R., Bedford, R., Abbruzzese, J. L., Lahoti, S., Reid, T. R., Soetikno, R. M., Kirn, D. H., and Freeman, S. M. A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma. Clin. Cancer Res. 9, 555-561 (2003).
39. Jounaidi, Y. and Waxman, D. J. Use of Replication-conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-activation Genes for Cancer Therapy. Cancer Res. 64, 292-303 (2004).
40. Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., and Kom, W. M. Loss of p14ARF in Tumor Cells Facilitates Replication of the Adenovirus Mutant d11520 (ONYX-015). Nat. Med. 6, 1128-1133 (2000).
41. Edwards, S. J., Dix, B. R., Myers, C. J., Dobson-Le, D., Huschtscha, L., Hibma, M., Royds, J., and Braithwaite, A. W. Evidence that Replication of the Antitumor Adenovirus ONYX-015 is not Controlled by the p53 and p14(ARF) Tumor Suppressor Genes. J. Virol. 76, 12483-12490 (2002).
42. Harada, J. N. and Berk, A. J. p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication. J. Virol. 73, 5333-5344 (1999).
43. Shen, Y., Kitzes, G., Nye, J. A., Fattaey, A., and Hermiston, T. Analyses of Single-amino-acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein. J. Virol. 75, 4297-4307 (2001).
44. Johnson, L., Shen, A., Boyle, L., Kunich, J., Pandey, K., Lemmon, M., Hermiston, T., Giedlin, M., McCormick, F., and Fattaey, A. Selectively Replicating Adenoviruses Targeting Deregulated E2F Activity are Potent, Systemic Antitumor Agents. Cancer Cell 1, 325-337 (2002).
45. Li, D., Day, K. V., Yu, S., Shi, G., Liu, S., Guo, M., Xu, Y., Sreedharan, S., and O'Malley, B.W. Jr. The Role of Adenovirus-mediated Retinoblastoma 94 in the Treatment of Head and Neck Cancer. Cancer Res. 62, 4637-4644 (2002).
46. Zhang, X., Multani, A. S., Zhou, J. H., Shay, J. W., McConkey, D., Dong, L., Kim, C., S., Rosser, C. J., Pathak, S., and Benedict, W. F. Adenoviral-mediated Retinoblastoma 94 Produces Rapid Telomere Erosion, Chromosomal Crisis, and Caspase-dependent Apoptosis in Bladder Cancer and Immortalized Human Urothelial Cells but Not in Normal Urothelial Cells. Cancer Res. 63, 760-765 (2003).
47. Chiu, S. J., Ueno, N. T., and Lee, R. J. Tumor-targeted Gene Delivery Via Anti-HER2 Antibody (Trastuzumab, Herceptin®) Conjugated Polyethylenimine. J. Control Release 9, 357-369 (2004).
48. Oehring, R. D., Miletic, M., Valter, M. M., Pietsch, T., Neumann, J., Fimmers, R., and Schlegel, U. Vascular Endothelial Growth Factor (VEGF) in Astrocytic Gliomas - A Prognostic Factor? J. Neurooncol. 45, 117-125 (1999).
49. Valter, M. M., Hugel, A., Huang, H. J., Cavenee, W. K., Wiestler, O. D., Pietsch, T., and Wernert, N. Expression of the Ets-1 Transcription Factor in Human Astrocytomas is Associated with Fms-like Tyrosine Kinase-1 (Flt-1)/Vascular Endothelial Growth Factor Receptor-1 Synthesis and Neoangiogenesis. Cancer Res. 59, 5608-5614 (1999).
50. Huang, H., Cheville, J. C., Pan, Y., Roche, P. C., Schmidt, L. J., and Tindall, D. J. PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression. J. Biol. Chem. 276, 38830-38836 (2001).
51. Tanaka, M. and Grossman, H. B. In Vivo Gene Therapy of Human Bladder Cancer with PTEN Suppresses Tumor Growth, Downregulates Phosphorylated Akt, and Increases Sensitivity to Doxorubicin. Gene Ther. 10, 1636-1642 (2003).
52. Waxman, D. J. and Schwartz, P. S. Harnessing Apoptosis for Improved Anticancer Gene Therapy. Cancer Res. 63, 8563-8572 (2003).
53. Chen, L. and Waxman, D. J. Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines Following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy. Cancer Res. 55, 581-589 (1995).
54. Chen, L., Yu, L. J., and Waxman, D. J. Potentiation of Cytochrome P450/Ccyclophosphamide-based Cancer Gene Therapy by Coexpression of the P450 Reductase Gene. Cancer Res. 57, 4830-4837 (1997).
55. Wei, M. X., Tamiya, T., Chase, M., Boviatsis, E. J., Chang, T. K., Kowall, N. W., Hochberg, F. H., Waxman, D.J., Breakefield, X. O., and Chiocca, E. A. Experimental Tumor Therapy in Mice Using the Cyclophosphamide-activating Cytochrome P450 2B1 Gene. Hum. Gene Ther. 5, 969-978 (1994).
56. Buller, R. E., Runnebaum, I. B., Karlan, B. Y., Horowitz, J. A., Shahin, M., Buekers, T., Petrauskas, S., Kreienberg, R., Slamon, D., and Pegram, M. A Phase I/II Trial of rAd/p53 (SCH 58500) Gene Replacement in Recurrent Ovarian Cancer. Cancer Gene Ther. 9, 553-566 (2002).
57. Chen, G. and Waxman, D. J. Role of Cellular Glutathione and Glutathione S-transferase in the Expression of Alkylating Agent Cytotoxicity in Human Breast Cancer Cells. Biochem. Pharmacol. 47, 1079-1087 (1994).
58. Waxman, D. J. Glutathione S-transferases: Role in Alkylating Agent Resistance and Possible Target for Modulation Chemotherapy - A Review. Cancer Res. 50, 6449-6454 (1990).
59. Sladek, N. E. Aldehyde Dehydrogenase-mediated Cellular Relative Insensitivity to the Oxazaphosphorines. Curr. Pharm. Des. 5, 607-625 (1999).
60. Schwartz, P. S., Chen, C. S., and Waxman, D. J. Enhanced Bystander Cytotoxicity of P450 Gene-directed Enzyme Prodrug Therapy by Expression of the Antiapoptotic Factor p35. Cancer Res. 62, 6928-6937 (2002).
61. Clem, R. J. and Miller, L. K. Control of Programmed Cell Death by the Baculovirus Genes p35 and iap. Mol. Cell. Biol. 14, 5212-5222 (1994).
62. Altieri, D. C. Validating Survivin as a Cancer Therapeutic Target. Nat. Rev. Cancer 3, 46-54 (2003).
63. Hersey, P. and Zhang, X. D. Overcoming Resistance of Cancer Cells to Apoptosis. J. Cell Physiol. 196, 9-18 (2003).
64. Lock, R. B. and Stribinskiene, L. Dual Modes of Death Induced by Etoposide in Human Epithelial Tumor Cells Allow Bcl-2 to Inhibit Apoptosis Without Affecting Clonogenic Survival. Cancer Res. 56, 4006-4012 (1996).
65. Yin, D. X. and Schimke, R. T. BCL-2 Expression Delays Drug-induced Apoptosis but Does Not Increase Clonogenic Survival After Drug Treatment in HeLa Cells. Cancer Res. 55, 4922-4928 (1995).
66. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S., and Reed, J. C. The c-IAP-1 and c-IAP-2 Proteins are Direct Inhibitors of Specific Caspases. Embo J. 16, 6914-6925 (1997).
67. Xue, L., Fletcher, G. C., and Tolkovsky, A.M. Mitochondria are Selectively Eliminated from Eukaryotic Cells after Blockade of Caspases During Apoptosis. Curr. Biol. 11, 361-365 (2001).
68. Deveraux, Q. L., Roy, N., Stennicke, H. R., Van Arsdale, T., Zhou, Q., Srinivasula, S. M., Alnemri, E. S., Salvesen, G. S., and Reed, J. C. IAPs Block Apoptotic Events Induced by Caspase-8 and Cytochrome c by Direct Inhibition of Distinct Caspases. Embo. J. 17, 2215-2223 (1998).
69. Sheikh, M. S. and Fornace, A. J., Jr. Death and Decoy Receptors and p53-mediated Apoptosis. Leukemia 14, 1509-1513 (2000).
70. Bortul, R., Tazzari, P. L., Cappellini, A., Tabellini, G., Billi, A. M., Bareggi, R., Manzoli, L., Cocco, L., and Martelli, A. M. Constitutively Active Akt1 Protects HL60 Leukemia Cells from TRAIL-induced Apoptosis Through a Mechanism Involving NF-kappaB Activation and cFLIP(L) Up-regulation. Leukemia 17, 379-389 (2003).
71. Kim, S. H., Kim, J. H., and Djordjevic, B. Effects of x-irradiation on RNA and Protein Synthesis in HeLa Cells. Radiat. Res. 42, 577-589 (1970).
72. Hallahan, D. E., Virudachalam, S., Beckett, M., Sherman, M. L., Kufe, D., and Weichselbaum, R. R. Mechanisms of X-ray-mediated Protoonco-gene c-jun Expression in Radiation-induced Human Sarcoma Cell Lines. Int. J. Radiat. Oncol. Biol. Phys. 21, 1677-1681 (1991).
73. Chastel, C., Jiricny, J., and Jaussi, R. Activation of Stress-responsive Promoters by Ionizing Radiation for Deployment in Targeted Gene Therapy. DNA Repair (Amst) 3, 201-215 (2004).
74. Brach, M. A., Hass, R., Sherman, M. L., Gunji, H., Weichselbaum, R., and Kufe, D. Ionizing Radiation Induces Expression and Binding Activity of the Nuclear Factor kappa B. J. Clin. Invest. 88, 691-695 (1991).
75. Hallahan, D. E., Sukhatme, V.P., Sherman, M.L., Virudachalam, S., Kufe, D., and Weichselbaum, R. R. Protein Kinase C Mediates X-ray Inducibility of Nuclear Signal Transducers EGR1 and JUN. Proc. Natl. Acad. Sci. USA 88, 2156-2160 (1991).
76. Hallahan, D. E., Virudachalam, S., Sherman, M. L., Huberman, E., Kufe, D. W., and Weichselbaum, R.R. Tumor Necrosis Factor Gene Expression is Mediated by Protein Kinase C Following Activation by Ionizing Radiation. Cancer Res. 51, 4565-4569 (1991).
77. Weichselbaum, R. R., Hallahan, D. E., Sukhatme, V. P., and Kufe, D. W. Gene Therapy Targeted by Ionizing Radiation. Int. J. Radiat. Oncol. Biol. Phys. 24, 565-567 (1992).
78. Hallahan, D. E., Beckett, M. A., Kufe, D., and Weichselbaum, R. R. The Interaction Brecombinant Human Tumor Necrosis Factor and Radiation in 13 Human Tumor Cell Lines. Int. J. Radiat. Oncol. Biol. Phys. 19, 69-74 (1990).
79. Hallahan, D. E., Mauceri, H. J., Seung, L. P., Dunphy, E. J., Wayne, J. D., Hanna, N. N., Toledano, A., Hellman, S., Kufe, D. W., and Weichselbaum, R. R. Spatial and Temporal Control of Gene Therapy Using Ionizing Radiation. Nat. Med. 1, 786-791 (1995).
80. Chung, T. D., Mauceri, H. J., Hallahan, D. E., Yu, J. J., Chung, S., Grdina, W. L., Yajnik, S., Kufe, D. W., and Weichselbaum, R. R. Tumor Necrosis Factor-alpha-based Gene Therapy Enhances Radiation Cytotoxicity in Human Prostate Cancer. Cancer Gene Ther. 5, 344-349 (1998).
81. Mauceri, H. J., Seetharam, S., Beckett, M. A., Lee, J. Y., Gupta, V. K., Gately, S., Stack, M. S., Brown, C. K., Swedberg, K., Kufe, D. W., and Weichselbaum, R. R. Tumor Production of Angiostatin is Enhanced after Exposure to TNF-alpha. Int. J. Cancer 97, 410-415 (2002).
82. Senzer, N., Mani, S., Rosemurgy, A., Nemunaitis, J., Cunningham, C., Guha, C., Bayol, N., Gillen, M., Chu, K., Rasmussen, C., Rasmussen, H., Kufe, D., Weichselbaum, R., and Hanna, N. TNFerade Biologic, An Adenovector with a Radiation-inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients with Solid Tumors. J. Clin. Oncol. 22, 592-601 (2004).
83. Markert, J. M., Malick, A., Coen, D. M., and Martuza, R. L. Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir. Neurosur-gery 32, 597-603 (1993).
84. Chou, J. and Roizman, B. The Gamma 1(34.5) Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programed Cell Death in Neuronal Cells. Proc. Natl. Acad. Sci. USA 89, 3266-3270 (1992).
85. Advani, S. J., Sibley, G.S., Song, P.Y., Hallahan, D.E., Kataoka, Y., Roizman, B., and Weichselbaum, R. R. Enhancement of Replication of Genetically Engineered Herpes Simplex Viruses by Ionizing Radiation: A New Paradigm for Destruction of Therapeutically Intractable Tumors. Gene Ther. 5, 160-165 (1998).
86. Schoensiegel, F., Paschen, A., Sieger, S., Eskerski, H., Mier, W., Rothfels, H., Kleinschmidt, J., Schadendorf, D., and Haberkorn, U. MIA (Melanoma Inhibitory Activity) Promoter Mediated Tissue-specific Suicide Gene Therapy of Malignant Melanoma. Cancer Gene Ther. 11, 408-418 (2004).
87. Tan, J. and Hallahan, D. Growth Factor-independent Activation of Akt Contributes to the Viability of Irradiated Vascular Endothelium. Int. J. Radiat. Oncol. Biol. Phys. 57 (2 Suppl), S316-317 (2003).
88. Tan, J. and Hallahan, D. E. Growth Factor-independent Activation of Protein Kinase B Contributes to the Inherent Resistance of Vascular Endothelium to Radiation-induced Apoptotic Response. Cancer Res. 63, 7663-7667 (2003).
89. Lu, B., Mu, Y., Cao, C., Zeng, F., Schneider, S., Tan, J., Price, J., Chen, J., Freeman, M., and Hallahan, D. E. Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer. Cancer Res. 64, 2840-2845 (2004).
90. Helene, C. and Toulme, J. J. Specific Regulation of Gene Expression by Antisense, Sense and Antigene Nucleic Acids. Biochim. Biophys. Acta. 1049, 99-125 (1990).
91. Peyman, A., Helsberg, M., Kretzschmar, G., Mag, M., Grabley, S., and Uhlmann, E. Inhibition of Viral Growth by Antisense Oligonucleotides Directed Against the IE110 and the UL30 mRNA of Herpes Simplex Virus Type-1. Biol. Chem. Hoppe. Seyler. 376, 195-198 (1995).
92. Smith, L., Andersen, K. B., Hovgaard, L., and Jaroszewski, J. W. Rational Selection of Antisense Oligonucleotide Sequences. Eur. J. Pharm. Sci. 11, 191-198 (2000).
93. Crooke, S. T. Progress in Antisense Therapeutics. Hematol. Pathol. 9, 59-72 (1995).
94. Zhang, Z., Wang, H., Li, M., Agrawal, S., Chen, X., and Zhang, R. MDM2 is a Negative Regulator of p21WAF1/CIP1, Independent of p53. J. Biol. Chem. 279, 16000-16006 (2004).
95. Wang, H., Nan, L., Yu, D., Agrawal, S., and Zhang, R. Antisense Anti-MDM2 Oligonucleotides as a Novel Therapeutic Approach to Human Breast Cancer: In Vitro and In Vivo Activities and Mechanisms. Clin. Cancer Res. 7, 3613-3624 (2001).
96. Freedman, D. A. and Levine, A. J. Regulation of the p53 Protein by the MDM2 Oncoprotein - Thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 59, 1-7 (1999).
97. Mu, Z., Hachem, P., Agrawal, S., and Pollack, A. Antisense MDM2 Sensitizes Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination. Int. J. Radiat. Oncol. Biol. Phys. 58, 336-343 (2004).
98. Dilla, T., Romero, J., Sanstisteban, P., and Velasco, J. A. The mdm2 Proto-oncogene Sensitizes Human Medullary Thyroid Carcinoma Cells to Ionizing Radiation. Oncogene 21, 2376-2386 (2002).
99. Orr, R. M. Technology Evaluation: Fomivirsen, Isis Pharmaceuticals Inc/CIBA Vision. Curr. Opin. Mol. Ther. 3, 288-294 (2001).
100. Kamiyama, M., Ichikawa, Y., Ishikawa, T., Chishima, T., Hasegawa, S., Hamaguchi, Y., Nagashima, Y., Miyagi, Y., Mitsuhashi, M., Hyndman, D., Hoffman, R. M., Ohki, S., and Shimada, H. VEGF Receptor Antisense Therapy Inhibits Angiogenesis and Peritoneal Dissemination of Human Gastric Cancer in Nude Mice. Cancer Gene Ther. 9, 197-201 (2002).
101. Shi, Y. Mechanisms of Caspase Activation and Inhibition During Apoptosis. Mol. Cell 9, 459-470 (2002).
102. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. Duplexes of 21-nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells. Nature 411, 494-498 (2001).
103. Fire, A., Xu, S., Montgomery, M. K., Kostas, S.A., Driver, S. E., and Mello, C. C. Potent and Specific Genetic Interference by Double-stranded RNA in Caenorhabditis Elegans. Nature 391, 806-811 (1998).
104. Sharp, P. A. RNA Interference - 2001. Genes Dev. 15, 485-490 (2001).
105. Hamilton, A. J. and Baulcombe, D.C. A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants. Science 286, 950-952 (1999).
106. Hammond, S. M., Bernstein, E., Beach, D., and Hannon, G. J. An RNA-directed Nuclease Mediates Post-transcriptional Gene Silencing in Drosophila Cells. Nature 404, 293-296 (2000).
107. Zamore, P. D. Ancient Pathways Programmed by Small RNAs. Science 296, 1265-1269 (2002).
108. Dykxhoorn, D. M., Novina, C. D., and Sharp, P. A. Killing the Messenger: Short RNAs that Silence Gene Expression. Nat. Rev. Mol. Cell Biol. 4, 457-467 (2003).
109. Kawasaki, H. and Taira, K. Short Hairpin Type of dsRNAs That are Controlled by tRNA(Val) Promoter Significantly Induce RNAi-mediated Gene Silencing in the Cytoplasm of Human Cells. Nucleic Acids Res. 31, 700-707 (2003).
110. Kawasaki, H., Tsunemi, M., Iyo, M., Oshima, K., Minoshima, H., Hamada, A., Onuki, R., Suyama, E., and Taira, K. A Functional Gene Discovery in Cell Differentiation by Hybrid Ribozyme and siRNA Libraries. Nucleic Acids Res. Suppl. 275-276 (2002).
111. Futami, T., Miyagishi, M., Seki, M., and Taira, K. Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against bcl-2. Nucleic Acids Res. Suppl. 251-252 (2002).
112. Miyagishi, M. and Taira, K. Development and Application of siRNA expression Vector. Nucleic Acids Res. Suppl. 113-114 (2002).
113. Hamada, M., Ohtsuka, T., Kawaida, R., Koizumi, M., Morita, K., Furukawa, H., Imanishi, T., Miyagishi, M., and Taira, K. Effects on RNA Interference in Gene Expression (RNAi) in Cultured Mammalian Cells of Mismatches and the Introduction of Chemical Modifications at the 3'-ends of siRNAs. Antisense Nucleic Acid Drug Dev. 12, 301-309 (2002).
114. Takagi, Y., Suyama, E., Kawasaki, H., Miyagishi, M., and Taira, K. Mechanism of Action of Hammerhead Ribozymes and Their Applications In Vivo: Rapid Identification of Functional Genes in the Post-genome Era by Novel Hybrid Ribozyme Libraries. Biochem. Soc. Trans. 30, 1145-1149 (2002).
115. Miyagishi, M. and Taira, K. U6 Promoter-driven siRNAs with Four Uridine 3′ Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells. Nat. Biotechnol. 20, 497-500 (2002).
116. Akashi, H., Miyagishi, M., and Taira, K. Suppression of Gene Expression by RNA Interference in Cultured Plant Cells. Antisense Nucleic. Acid Drug Dev. 11, 359-367 (2001).
117. Tomar, R. S., Matta, H., and Chaudhary, P. M. Use of Adeno-associated Viral Vector for Delivery of Small Interfering RNA. Oncogene 22, 5712-5715 (2003).
118. Matta, H., Hozayev, B., Tomar, R., Chugh, P., and Chaudhary, P. M. Use of Lentiviral Vectors for Delivery of Small Interfering RNA. Cancer Biol. Ther. 2, 206-210 (2003).
119. Hagstrom, J. E., Hegge, J., Zhang, G., Noble, M., Budker, V., Lewis, D. L., Herweijer, H., and Wolff, J. A. A Facile Nonviral Method for Delivering Genes and siRNAs to Skeletal Muscle of Mammalian Limbs. Mol. Ther. 10, 386-398 (2004).
120. Lewis, D. L., Hagstrom, J. E., Loomis, A. G., Wolff, J. A., and Herweijer, H. Efficient Delivery of siRNA for Inhibition of Gene Expression in Postnatal Mice. Nat. Genet. 32, 107-108 (2002).
121. Chen, J., Wall, N. R., Kocher, K., Duclos, N., Fabbro, D., Neuberg, D., Griffin, J. D., Shi, Y., and Gilliland, D. G. Stable Expression of Small Interfering RNA Sensitizes TEL-PDGFbetaR to Inhibition with Imatinib or Rapamycin. J. Clin. Invest. 113, 1784-1791 (2004).
122. Guo, J., Verma, U. N., Gaynor, R. B., Frenkel, E. P., and Becerra, C. R. Enhanced Chemosensitivity to Irinotecan by RNA Interference-mediated Down-regulation of the Nuclear Factor-kappaB p65 Subunit. Clin. Cancer Res. 10, 3333-3341 (2004).
123. Duxbury, M. S., Ito, H., Benoit, E., Zinner, M. J., Ashley, S. W., and Whang, E. E. RNA Interference Targeting Focal Adhesion Kinase Enhances Pancreatic Adenocarcinoma Gemcitabine Chemo-sensitivity. Biochem. Biophys. Res. Commun. 311, 786-792 (2003).
124. Peng, Y., Zhang, Q., Nagasawa, H., Okayasu, R., Liber, H. L., and Bedford, J. S. Silencing Expression of the Catalytic Subunit of DNA-dependent Protein Kinase by Small Interfering RNA Sensitizes Human Cells for Radiation-induced Chromosome Damage, Cell Killing, and Mutation. Cancer Res. 62, 6400-6404 (2002).
125. Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., and Muramatsu, T. A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics. Cancer Res. 64, 3365-3370 (2004).
126. Edwards, E., Geng, L., Tan, J., Onishko, H., Donnelly, E., and Hallahan, D. E. Phosphatidylinositol 3-kinase/Akt Signaling in the Response of Vascular Endothelium to Ionizing Radiation. Cancer Res. 62, 4671-4677 (2002).